The estimated Net Worth of Donald P Braun is at least $10.5 Mille dollars as of 17 May 2021. Donald Braun owns over 5,000 units of Imunon Inc stock worth over $10,500 and over the last 9 years he sold CLSN stock worth over $0. In addition, he makes $0 as Independent Director at Imunon Inc.
Donald has made over 1 trades of the Imunon Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of CLSN stock worth $5,350 on 17 May 2021.
The largest trade he's ever made was buying 5,000 units of Imunon Inc stock on 17 May 2021 worth over $5,350. On average, Donald trades about 385 units every 0 days since 2015. As of 17 May 2021 he still owns at least 5,357 units of Imunon Inc stock.
You can see the complete history of Donald Braun stock trades at the bottom of the page.
Dr. Donald P. Braun has been appointed an Independent Director at Celsion Corporation effective December 15, 2015. He has over 30 years of research expertise in oncology, with a focus on immunotherapy and the effectiveness and impact of chemotherapy protocols on various cancers and tumor types, and currently serves as Vice President Translational Research and Chief Science Officer at the Cancer Treatment Centers of America. Prior to his current role, he was the Scientific Director of the Cancer Center and Professor of Medicine and Immunology at Rush Medical College in Chicago, and the Administrative Director of the Cancer Institute and a Professor of Surgery with tenure at the Medical College of Ohio. Dr. Braun has been appointed to and served on more than a dozen federal government and public advisory committees on oncology and immunology. He received his Ph.D. in Immunology and Microbiology from the University of Illinois at the Medical Center in Chicago.
Donald's mailing address filed with the SEC is C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE, NJ, 08648.
Over the last 17 years, insiders at Imunon Inc have traded over $895,739 worth of Imunon Inc stock and bought 973,579 units worth $2,229,348 . The most active insiders traders include Gary W Pace, Max Link e Sean F. Moran. On average, Imunon Inc executives and independent directors trade stock every 38 days with the average trade being worth of $22,407. The most recent stock trade was executed by Michael H Tardugno on 12 April 2022, trading 4,000 units of CLSN stock currently worth $14,120.
Celsion is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative cancer treatments, including immunotherapies and DNA-based therapies; and a platform for the development of nucleic acid vaccines currently focused on SARS-CoV2. The company's product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer. ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, is under investigator-sponsored development for several cancer indications. Celsion also has two feasibility stage platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. Both are novel synthetic, non-viral vectors with demonstrated capability in nucleic acid cellular transfection.
Imunon Inc executives and other stock owners filed with the SEC include: